

12/2/20

- 5



15

2. A composition according to claim 1 wherein the guest molecule preferably has a relative molecular weight in the range 16 to 150.
3. A composition according to claim 1 wherein the guest molecule contains a moiety capable of acting as a hydrogen bond acceptor.
4. A composition according to claim 1 wherein the guest molecule is selected from the list consisting of cyclopentanone, dimethylsulfoxide, ethanol, propan-1-ol, butan-1-ol, 1,4-dioxane, ethyl formate, methyl acetate, water and acetic acid,
5. A composition according to claim 1 wherein the guest molecule is acetone.
6. A composition according to claim 1 wherein the guest molecule is methylethylketone.
7. A composition according to claim 1 wherein the guest molecule is tetrahydrofuran.
8. A composition according to claim 1 wherein the guest molecule is propan-2-ol.

- Sub
Pi
cont.
- 5
9. A composition according to claim 1 wherein the guest molecule is dimethylformamide.
10. A composition according to claim 1 wherein the guest molecule is butan-1-ol
11. A composition according to claim 1 wherein the guest molecule is methyl acetate.
12. A composition according to claim 1 wherein the guest molecule is acetic acid.
13. A composition according to claim 1 wherein the guest molecule is propan-1-ol.
14. A composition according to claim 1 wherein the guest molecule is ethanol.
15. A composition according to claim 1 wherein the guest molecule is ethyl formate.
- 10
16. A composition according to claim 1 wherein the guest molecule is 1,4-dioxane.
17. A composition according to claim 1 wherein the guest molecule is dimethylsulphoxide.
- 15
18. A composition according to claim 1 wherein the guest molecule is N-methyl-2-pyrrolidinone.
19. A composition according to claim 1 wherein the guest molecule is dimethylacetamide.
- 20
20. A composition according to claim 1 wherein the guest molecule is cyclopentanone.
21. A composition according to claim 1 wherein the guest molecule is water.

22. A composition according to claim 1 wherein the guest molecule is ϵ -caprolactam.
23. A composition according to claim 4 wherein the ratio of compound of formula (I) to guest molecule is 1:2.0-0.3.
- 5 24. A pharmaceutical composition comprising a composition according to claim 1 together with a physiologically acceptable diluent or carrier.
- 10 25. A method for the treatment of a human or animal subject with an inflammatory and/or allergic condition, which method comprises administering to said human or animal subject an effective amount of the composition according to claim 1.
26. A pharmaceutical composition comprising a composition according to claim 1 in combination with another therapeutically active agent.
27. A composition according to claim 26 wherein the other therapeutically active ingredient is a long acting β_2 -adrenoreceptor agonist.
- 15 28. A process for preparing a composition according to claim 1 which comprises
(a) crystallising the composition from a solution containing a compound of formula (I) and the guest molecule; or
(b) contacting the compound of formula (I) or another composition according claim 1 in solid form with a liquid containing the guest molecule and obtaining the composition therefrom; or
(c) contacting a compound of formula (I) or another composition according to claim 1 in solid form with a vapour containing the guest molecule.
- 20 29. A process for preparing compound of formula (I) in unsolvated form in the form of equant or substantially equant particles by a process comprising:
(a) preparing a composition according to claim 1 in the form of equant or substantially equant particles; and
(b) removing the guest molecule.
- 25 30. A process according to claim 29 wherein the composition is a composition with propan-2-ol or acetone as guest molecule.
- 30